Clopidogrel Tablet, Film Coated
Product Images NDC 0093-7314

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 0093-7314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Clopidogrel Bisulfate (Image 1)

Chemical structure of the active ingredient Clopidogrel bisulfate, as shown by its molecular diagram including characteristic rings and side groups with sulfate indicated.*

FDA Label Image

Figure-08.jpg (Image 10)

A forest plot comparing outcomes between Clopidogrel and Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. It includes hazard ratios with 95% confidence intervals, depicting favorability towards either Clopidogrel or Aspirin. The plot presents numerical event counts and percentages for both drugs in each condition.*

FDA Label Image

Image (Image 11)

Clopidogrel Tablets, USP 75 mg film-coated oral tablets by Teva Pharmaceuticals USA, Inc. The label shows the product name, strength, and dosage form, with a package count of 30 tablets. It includes NDC 0093-7314, directions to dispense the accompanying Medication Guide, and storage information. The Teva logo is visible on the bottom right.*

FDA Label Image

Figure 1 (Image 2)

A scatter plot with confidence intervals illustrating the effect of coadministered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel. The x-axis shows the change relative to clopidogrel administered alone, ranging from 0.4 to 1.4. Data points include Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, each with associated error bars indicating mean and 90% confidence intervals.*

FDA Label Image

Figure 2 (Image 3)

A line graph depicting cumulative event rates for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two treatment groups are compared: Clopidogrel (+ aspirin) and placebo (+ aspirin), showing lower cumulative event rates with Clopidogrel throughout the study period. The graph includes a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure-03a.jpg (Image 4)

A forest plot chart illustrating the hazard ratios with 95% confidence intervals comparing the effects of Clopidogrel versus placebo across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction (MI), and previous stroke. The chart shows the number of subjects and event percentages for Clopidogrel and placebo groups along with graphical representations of hazard ratios favoring either treatment.*

FDA Label Image

Figure-03b.jpg (Image 5)

A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel to placebo across subgroups defined by concomitant treatments including Heparin/LMWH, Aspirin dose, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use, along with an overall summary. The x-axis represents hazard ratios from 0.3 to 1.4, with markers indicating effect sizes favoring Clopidogrel or placebo for each subgroup.*

FDA Label Image

Figure 4 (Image 6)

A Kaplan-Meier survival curve chart showing percentage of deaths before first discharge over 28 days since randomization. It compares two groups: one receiving Clopidogrel with 1726 deaths (7.5%) and the other a placebo group with 1845 deaths (8.1%). The chart notes a 7% proportional risk reduction (p=0.03) associated with Clopidogrel.*

FDA Label Image

Figure 5 (Image 7)

This is a line graph showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. It compares two groups: one receiving placebo and another receiving Clopidogrel. The graph displays event rates and mentions a 9% proportional risk reduction with Clopidogrel.*

FDA Label Image

Figure-06.jpg (Image 8)

A data table presenting subgroup analyses comparing Clopidogrel tablets 75 mg with placebo across various categories including gender, age, hours since onset, systolic blood pressure, heart rate, and use of fibrinolytic agents. It shows patient counts, percentages, and odds ratios with confidence intervals indicating the relative favorability of Clopidogrel versus placebo in each subgroup.*

FDA Label Image

Figure 8 (Image 9)

A line graph depicting cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up. The graph compares two lines labeled 'Aspirin' and 'Clopidogrel.' The y-axis is labeled 'Cumulative Event Rate [%]' from 0 to 16, and the x-axis is labeled 'Months of Follow-Up' from 0 to 36. A p-value of 0.045 is marked on the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.